Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria — United States, 2019

Julia C. Haston, MD; Jimee Hwang, MD; Kathrine R. Tan, MD

Disclosures

Morbidity and Mortality Weekly Report. 2019;68(42):1062-1068. 

In This Article

Methods

CDC conducted a search of English-language articles available in PubMed, Ovid Medline, Scopus, and Global Health (CABDirect) on January 17, 2019, using keywords "tafenoquine or WR238605" and "prevent, prevention, prophylaxis, treatment, radical, or cure." A total of 269 articles were collated and underwent title, abstract, and full text reviews by two physicians: an infectious disease specialist and a malaria subject matter expert. The references from review articles and meta-analyses, and the FDA labeling for both Krintafel and Arakoda were also reviewed to identify any additional studies. Randomized, double-blind, controlled trials performed in human subjects using the labeled recommended dosing regimens were preferentially included in the final review. Data on dosing regimen, outcome, and adverse events were abstracted. Based on the results of the review, CDC subject matter experts developed guidance for the use of tafenoquine.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....